Statins and cancer: A systematic review and meta-analysis

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2122-2132

  Kuoppala, Jaana ^a   Lamminpää, Anne ^b   Pukkala, Eero ^a  

^a FINNISH CANCER REGISTRY   (Finland)

^b State Treasury   (Finland)

Author keywords

Cancer; Meta analysis; Neoplasms; Statins; Systematic review

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER THERAPY; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; EMBASE; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MEDLINE; MELANOMA; META ANALYSIS; MYELOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SKIN CANCER; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT CANCER; UROGENITAL TRACT CANCER;

EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 54849131100     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.025     Document Type: Article

References (74)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 9493 (2005) 1267-1278
2. Chan K.K., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin Cancer Res 9 1 (2003) 10-19
3. Thibault A., Samid D., Tompkins A.C., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 3 (1996) 483-491
4. Simons M. Molecular multitasking: Statins lead to more arteries, less plaque. Nat Med 6 9 (2000) 965-966
5. Bonovas S., Filioussi K., Tsavaris N., and Sitaras N.M. Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24 30 (2006) 4808-4817
6. Browning D.R., and Martin R.M. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 120 4 (2007) 833-843
7. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: A meta-analysis. JAMA 295 1 (2006) 74-80
8. Roberts C.G., Guallar E., and Rodriguez A. Efficacy and safety of statin monotherapy in older adults: A meta-analysis. J Gerontol A Biol Sci Med Sci 62 8 (2007) 879-887
9. Dellavalle R.P., Drake A., Graber M., et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 4 (2005) CD003697
10. Freeman S.R., Drake A.L., Heilig L.F., et al. Statins, fibrates, and melanoma risk: A systematic review and meta-analysis. J Natl Cancer Inst 98 21 (2006) 1538-1546
11. Stein E.A., Corsini A., Gimpelewicz C.R., Bortolini M., and Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract 60 9 (2006) 1028-1034
12. Taylor M.L., Wells B.J., and Smolak M.J. Statins and cancer: A meta-analysis of case-control studies. Eur J Cancer Prev 17 3 (2008) 259-268
13. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. for the MARS Research Group. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119 10 (1993) 969-976
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
15. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 7 (1995) 1758-1764
16. Jukema J.W., Bruschke A.V.G., Van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 10 (1995) 2528-2540
17. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 333 (1995) 1301-1307
18. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101 (1996) 627-634
19. Sacks F.M., Pfefeer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 335 14 (1996) 1001-1009
20. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80 3 (1997) 278-286
21. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
22. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 339 (1998) 1349-1357
23. Marchioli R. Results of the low-dose (20 Mg) pravastatin GISSI Prevenzione Trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge?. Ital Heart J 1 (2000) 810-820
24. Serruys P.W., de F.P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287 (2002) 3215-3222
25. Collins R., Armitage J., Parish S., Sleight P., and Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
26. Shepherd J., Blauw G.J., Murphy M.B., et al. PROSPER-study-group. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
27. Beishuizen E.D., Van De Ree M.A., Jukema J.W., et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 27 12 (2004) 2887-2892
28. Zanchetti A., Crepaldi G., Bond M.G., et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: Principal results of PHYLLIS - A randomized double-blind trial. Stroke 35 12 (2004) 2807-2812
29. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 3 (2005) 238-248
30. Beck P., Wysowski D.K., Downey W., and Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 56 3 (2003) 280-285
31. Cauley J.A., Zmuda J.M., Lui L.Y., et al. Lipid-lowering drug use and breast cancer in older women: A prospective study. J Women's Health 12 8 (2003) 749-756
32. Friis S., Poulsen A.H., Johnsen S.P., et al. Cancer risk among statin users: A population-based cohort study. Int J Cancer 114 4 (2005) 643-647
33. Eliassen A.H., Colditz G.A., Rosner B., Willett W.C., and Hankinson S.E. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165 (2005) 2264-2271
34. Wei J.T., Mott L.A., Baron J.A., and Sandler R.S. Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 14 4 (2005) 1026-1027
35. Cauley J.A., McTiernan A., Rodabough R.J., et al. Statin use and breast cancer: Prospective results from the Women's Health Initiative. J Natl Cancer Inst 98 10 (2006) 700-707
36. Jacobs E.J., Rodriguez C., Brady K.A., Connell C.J., Thun M.J., and Calle E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 98 1 (2006) 69-72
37. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 24 (2006) 1819-1825
38. Boudreau D.M., Yu O., Miglioretti D.L., Buist D.S., Heckbert S.R., and Daling J.R. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16 3 (2007) 416-421
39. Setoguchi S., Glynn R.J., Avorn J., Mogun H., and Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115 1 (2007) 27-33
40. Blais L., Desgagne A., and LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 160 15 (2000) 2363-2368
41. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., and Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol 22 12 (2004) 2388-2394
42. Kaye J.A., and Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90 3 (2004) 635-637
43. Vinogradova Y., Hippisley-Cox J., Coupland C., and Logan R.F. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: Nested case-control study. Gastroenterology 133 2 (2007) 393-402
44. Boudreau D.M., Gardner J.S., Malone K.E., Heckbert S.R., Blough D.K., and Daling J.R. The association between 3-hydroxy-3-methylglutaryl conenzyme, A inhibitor use and breast carcinoma risk among postmenopausal women: A case-control study. Cancer 100 11 (2004) 2308-2316
45. Zhang Y., Holford T.R., Leaderer B., et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15 (2004) 419-428
46. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 21 (2005) 2184-2192
47. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: A case-control study. Am J Epidemiol 162 4 (2005) 318-325
48. Fortuny J., de S.S., Becker N., et al. Statin use and risk of lymphoid neoplasms: Results from the European case-control study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15 5 (2006) 921-925
49. Iwata H., Matsuo K., Hara S., et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97 2 (2006) 133-138
50. Landgren O., Zhang Y., Hoar Zahm S., Inskip P., Zheng T., and Baris D. Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15 12 (2006) 2342-2347
51. Coogan P.F., Rosenberg L., and Strom B.L. Statin use and the risk of 10 cancers. Epidemiology 18 2 (2007) 213-219
52. Coogan P.F., Smith J., and Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 99 1 (2007) 32-40
53. Robertson D.J., Larsson H., Friis S., Pedersen L., Baron J.A., and Sorensen H.T. Proton pump inhibitor use and risk of colorectal cancer: A population-based, case-control study. Gastroenterology 133 3 (2007) 755-760
54. Khurana V., Bejjanki H.R., Caldito G., and Owens M.W. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 131 5 (2007) 1282-1288
55. Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 87 9 (2001) 1074-1079
56. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., and Cobbe S.M. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 15 (2007) 1477-1486
57. Khurana V., Sheth A., Caldito G., and Barkin J.S. Statins Reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas 34 2 (2007) 260-265
58. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 20 (1999) 725-741
59. Strandberg T.E., Pyörälä K., Cook T.J., et al. 4S-Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
60. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention With Pravastatin in Ischaemic Disease) Study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 76 (1995) 474-479
61. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID Trial follow-up. Lancet 2002; 359(9315): 1379-87.
62. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men age 45-64 years: Trial design. J Clin Epidemiol 45 (1992) 849-860
63. The West of Scotland Coronary Prevention Study Group. Computerised record linkage: Compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol 48 12 (1995) 1441-1452
64. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol 71 (1993) 393-400
65. Downs J.R., Beere P.A., Whitney E., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Design and rationale. Am J Cardiol 80 287 (1997) 293
66. Shepherd J., Blauw G.J., Murphy M.B., et al. on behalf of the PROSPER Study Group. The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol 84 (1999) 1192-1197
67. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
68. Baron J.A., Beach M., Mandel J.S., et al. for the Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenoma. N Engl J Med 340 (1999) 101-107
69. Greenberg E.R., Baron J.A., Tosteson T.D., et al. for the Polyp Prevention Study Group. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 331 (1994) 141-147
70. HPS Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: A randomised placebo-controlled trial [ISRCTN48489393]. BMC Medicine 3 6 (2005) 1-21
71. Calle E.E., Rodriguez C., Jacobs E.J., et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: Rational, study design and baseline characteristics. Cancer 94 (2002) 2490-2501
72. Scherer R.W., Langenberg P., and von E.E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2 (2007) MR000005
73. Bonovas S., and Sitaras N.M. Does pravastatin promote cancer in elderly patients?. A meta-analysis. CMAJ 176 5 (2007) 649-654
74. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 50 5 (2007) 409-418